RIL
INZY

Rothschild Investment LLC’s Inozyme Pharma INZY Stock Holding History

Rothschild Investment LLC’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-45
Closed -$41 – 3108
2025
Q1 		$41 Hold
45
– – ﹤0.01% 3003
2024
Q4 		$125 Buy
+45
New +$171 ﹤0.01% 2883
2024
Q3 		– Sell
-25
Closed -$112 – 2940
2024
Q2 		$112 Buy
+25
New +$121 ﹤0.01% 2706

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Rothschild Investment LLC's INZY Position: Q2 2025 in Review

Rothschild Investment LLC sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 45 shares — an estimated $41 sold.

Rothschild Investment LLC first reported a position in INZY in Q2 2024 and held it in 3 quarters. The position peaked at $125 in Q4 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Rothschild Investment LLC reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Rothschild Investment LLC sold 45 Inozyme Pharma shares in Q2 2025, an estimated $41.
  • Rothschild Investment LLC first reported a position in Inozyme Pharma in Q2 2024 and held it in 3 quarters.
  • Rothschild Investment LLC's Inozyme Pharma position peaked at $125 in Q4 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Rothschild Investment LLC's 13F filing for Q2 2025, filed 11 Aug 2025.